Wordt geladen...
Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22 Positive Hematologic Malignancies of Childhood: Pre-clinical Studies and Phase I Clinical Trial
PURPOSE: Although most children with B-lineage acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) are cured, new agents are needed to overcome drug resistance and reduce toxicities of chemotherapy. We hypothesized that the novel anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22, CAT-3888) w...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2010
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2840067/ https://ncbi.nlm.nih.gov/pubmed/20215554 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-2980 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|